Press Release

Glythera appoints Dr Mike Owen as non-executive director

Glythera Limited (‘Glythera’), the next generation antibody drug conjugate (‘ADC’) development company, is pleased to announce the appointment of Dr Mike Owen to the Board as a non-executive director with immediate effect. Mike brings over 15 years of experience in the development and commercialisation of biopharmaceuticals. He was previously Senior Vice President and global Head of Research of the Biopharmaceuticals R&D Unit  at GlaxoSmithKline and was responsible for initiating and rapidly growing GSK's robust pre-clinical and clinical therapeutic antibody pipeline…

Read more>>

Glythera launches UK government funded project to develop safer and more efficacious ADCs for the treatment of difficult-to-treat tumours

- Development of proprietary next generation ADC portfolio -  - Secures £1m in grant funding - Glythera Limited (‘Glythera’), the next generation antibody drug conjugate (‘ADC’) development company, today announces the launch of a £1 million Innovate UK grant-funded project to develop next-generation ADCs for difficult-to-treat tumours using Glythera’s proprietary non-maleimide conjugation platform, PermaLink®, in combination with its portfolio of novel toxins and antibodies. ADCs are an emerging class of targeted therapeutics in the fight against cancer. By combining the…

Read more>>

Glythera demonstrates improved activity and safety of PermaLink®-based ADCs

Glythera demonstrates improved activity and safety of PermaLink®-based ADCs    Appoints Scientific Advisory Board   -Significantly improved tolerability of ADCs incorporating highly potent toxins- - Efficacy outperforms industry-standard ADC technology – -Development of proprietary ADC pipeline supported by key industry appointments to SAB-   Glythera Limited (‘Glythera’), the next generation Antibody Drug Conjugate (‘ADC’) development company, today provides further evidence that PermaLink®, its proprietary non-maleimide conjugation platform, enables the production of ADCs with potentially greater clinical utility than current industry-standard…

Read more>>

 Last ›

Page 1 of 9